1Guo H,Zhou X,Jiang Y,et al.Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma:a Chinese experience[J].Am J Hematol,2010,85(7):499-501.
2Facon T,Mary JY,Pegourie B,et al.Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy[J].Blood,2006,107 (4):1292-1298.
3María VM,José MH,Miguel TH,et al.Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:updated time-to-events results and prognostic factors for time to progression[J].Haematologica,2008,93(4):560-565.
1Palumbo A, Facon T,Sonneveld P,et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 2008 ,111:3968-3977.
2Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol, 2002,20:4319-4323.
3International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders:a report of the International Myeloma Working Group. Br J Haematol, 2003, 121:749 -757.
4Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia, 2006, 20:1467 -1473.
5Blade J, Resinol L. Changing paradigmsin the troatment of multiple myeloma. Haematologica. 2009, 94:163- 166.
6Cavallo F, Boccadoro M, Palumbo A. Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther Clin Risk Manag, 2007, 3: 543-552.
7Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebocontrolled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed rnuhiple myeloma. J Clin Oncol, 2008, 26..2171-2177.
3Fcrlay J,Bray F,Pisani P ,et al GLOBOCAN 2002 Cancer Inci- dence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5 Version 2. 0. Lyon:I.ARC Press,20lM.
4Richardson P and Anderson K. Thalidomide and dexametha- sone: A new standard of care for initial therapy in multiple mye- loma [ J ]. J ClinOncol,2006,24 (3) :334 - 336.
5Dmoszynka A. Diagnosis and the current trends in multiple mye- lccna therapy [J]. Pol Arch Med Wewn,2008,118 (10):563 - 566.
6Singhal S, Mehta J, Desikan R, et al Antimmor activity of the thalidomide in refractory multiple mydoma [ J ]. N Engl J, 1999,341 (21) :1565 - 1571.
7Leleu X,Magro L,Fawaz A,et al Efficacy of a low dose of tha- lidomide in multiple mydoma [ J ]. Blood. 2002, ( 11 ) :100.
